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Background: To characterize the effect of combined treatment of the anti-epidermal growth factor receptor (EGFR)
monoclonal antibody C225 and 125-iodine (125I) seed radiation in human colorectal cancer.
Methods: We treated LS180 cells with 125I continuous low dose rate radiation in the presence and absence of 100
nM C225. The clonogenic capacity, cellular proliferation, cell cycle distribution, apoptosis, and molecular pathways
of the cells following the treatments were analyzed in vitro.
Results: The sensitizer enhancement ratio of C225 was approximately 1.4. Treatment with C225 and radiation alone
produced significant inhibition of cell growth, but combination therapy produced greater inhibition than either
treatment administered alone. C225 increased the radiation-induced apoptosis and the fraction of γ-H2AX foci
positive cells at 48 h after treatment. The Akt phosphorylation level was lower in the cells receiving the
combination treatment than in the cells treated with radiation or C225 alone.
Conclusions: These findings indicate that C225 sensitizes LS180 cells to 125I seed radiation. Growth inhibition is
mediated by inducing apoptosis and not cell cycle arrest. Additionally, we confirmed that C225 impairs DNA repair
by reducing the cellular level of the DNA-PKcs and Ku70 proteins. Furthermore, the inhibition of Akt signaling
activation may be responsible for the C225-mediated radiosensitization.
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Colorectal cancer (CRC) is the third most common
lethal disease, and it accounts for approximately one
million new cancer cases and approximately 10% of all
cancer deaths annually [1]. Preoperative radiochemo-
therapy administered concomitantly with 5-fluorouracil
has become the standard of care in rectal cancer,
especially in tumors of the lower and middle rectum [2].
Recently, high dose rate endorectal brachytherapy has
emerged as an alternative neoadjuvant treatment for
low-lying rectal cancer [3-5]. In our previous study, we
found that brachytherapy with low dose 125-iodine (125I)
seeds could serve as an effective salvage therapy for
recurring rectal cancer [6].
Epidermal growth factor receptor (EGFR) is known to
be overexpressed in a wide range of cancers, including
ovarian, brain, breast, colorectal, kidney, and pancreatic* Correspondence: junjiew920@sohu.com
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reproduction in any medium, provided the orcancers [7]. Multiple lines of evidence indicate that
EGFR is an important determinant of radioresponse and
has a radioprotective function. Based on current evi-
dence, EGFR-mediated radioprotection can be conceptu-
ally divided into three phases: (a) an immediate early
phase that involves DNA repair, (b) suppression of DNA
damage-induced apoptosis before and after cell cycle
arrest, and (c) a tumor repopulation step that offers
a proliferative advantage to tumors emerging from
radiation-induced cell cycle arrest [8]. Based on the ap-
preciation of the role of EGFR in cancer, several molecu-
larly targeted agents such as gefitinib, erlotinib, and
cetuximab (Erbitux, C225) have been developed to in-
hibit the activity of this receptor. Gefitinib and erlotinib
are FDA-approved as single agents for advanced non-
small cell lung cancer (NSCLC), and C225 has been ap-
proved for the treatment of advanced colon cancer in
combination with cisplatin and for head and neck squa-
mous cell carcinoma (HNSCC) in combination with ra-
diation [7].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Effect of C225 on radiation sensitivity. Cells were
exposed to continuous low dose rate radiation from 125-iodine
radioactive seeds with and without concurrent treatment of 100 nM
of C225. After the treatment, cells were cultured in fresh medium for
14–21 days to assay cell survival with colony formation assay. The
dose-survival curves were fitted by the single-hit multitarget model.
All data represent two independent experiments, mean ± SD. Two-
way ANOVA was used for data analysis. **P < 0.01, *P < 0.05
Table 1 In vitro radiobiological parameters of LS180 cells
(mean ± SD)
125I-CLDR C225 + 125I-CLDR
D0(Gy) 1.20 ± 0.15 0.86 ± 0.03
Dq(Gy) 0.62 ± 0.30 0.54 ± 0.06
N 1.67 ± 0.31 1.88 ± 0.10
SF2 0.30 ± 0.04 0.18 ± 0.01
The values for D0, Dq, and N were determined using the single-hit multitarget
model. d = D0 (
125I - CLDR)/D0 (C225 +
125I-CLDR). D0, Mean inactivation dose;
Dq, Quasi-threshold dose; N, extrapolation number; SF2, Survival fraction
at 2 Gy.
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ficacy of combined therapy of C225 with continuous low
dose rate (CLDR) radiation. C225 commonly produces
cytostatic effects that can prevent tumor cell repopula-
tion during the fractionated course of radiation [9]. The
short duration of time to deliver CLDR treatment repre-
sents a few doubling times for clonogenic cancer cells
[10]. Thus, C225 and CLDR treatments administered
together may have more cytostatic effects than either
treatment alone. If C225 could also produce a cytotoxic
effect and radiosensitization, its effect on reducing cell
survival of in colorectal cancer cells can be further
increased when combined with CLDR.
In the present study, we investigated the role of C225
in modulating the radioresponse of colorectal cancer
cells to 125I seed continuous low dose rate irradiation
(125I-CLDR) in vitro. Clonogenic and proliferation assays
revealed that C225 enhanced the antitumor effects of
125I-CLDR. While dissecting the mechanism underlying
this radiosensitization, we observed that C225 adminis-
tration increased 125I-CLDR-induced apoptosis and im-
paired the repair capacity of cellular DNA, but did not
affect 125I-CLDR-induced cell cycle arrest. These effects
of C225 on irradiation may have been mediated by its in-
hibition of Akt activation. In this study, we investigated the
combined effect of C225 therapy and 125I-CLDR in the
treatment of colorectal cancer.
Results
Sensitization of LS180 cells to radiation from 125I seeds
by C225
To assess the radiation-enhancing effects of C225, the
cells were exposed to CLDR from 125I seeds with and
without concurrent treatment with 100 nM of C225.
Figure 1 shows the survival curves of in LS180 cells for
treatment with radiation alone and in combination with
C225. In our study, the survival fraction at 1 Gy, 2 Gy,
4 Gy in 125I-CLDR treated cells was 0.61 ± 0.09, 0.30 ±
0.04, 0.05 ± 0.003, and the corresponding rate in C225 +
125I-CLDR group was 0.51 ± 0.02, 0.18 ± 0.01, 0.02 ± 0.006,
respectively. We found there were significant differences
concerning clonogenic survival between 125I-CLDR
and C225 + 125I-CLDR groups when we used two-way
ANOVA for data analysis. The sensitizer enhancement
ratio (SER) was approximately 1.4, indicating that
C225 increased the radiosensitivity of LS180 cells to
radiation from 125I seeds. The radiobiological parame-
ters of the LS180 cells are shown in Table 1.
C225 promotes the radiation-induced inhibition of
proliferation
We used the MTS proliferation assay to investigate
the growth-inhibitory effects of radiation and C225. As
shown in Figure 2A, C225 treatment and radiotherapyeach significantly inhibited LS180 cell growth when used
alone (72 h, Ctrl vs. C225, t = 25.5, P < 0.001; Ctrl vs.
125I-CLDR, t = 53.1, P < 0.001), but their combined in-
hibitory effect was greater than that produced by either
treatment alone (72 h, C225 + 125I-CLDR vs. C225, t =
31.5, P < 0.001; C225 + 125I-CLDR vs. 125I-CLDR, t = 3.7,
P < 0.01). To further clarify the inhibitory effects of
this combination, we detected the cell cycle distribution
at indicated times after treatment. G2/M cell cycle
arrest only appeared in 125I-CLDR and C225 + 125I-
CLDR treated group (0 h, Ctrl vs. C225, t = 2.4, P > 0.05;
Ctrl vs. 125I-CLDR, t = 3.5, P < 0.01; Ctrl vs. C225 + 125I-
CLDR, t = 4.8, P < 0.001), but disappeared at 24 h after
treatment (24 h, Ctrl vs. 125I-CLDR, t = 1.6, P > 0.05; Ctrl
vs. C225 + 125I-CLDR, t = 1.7, P > 0.05). G1 cell cycle ar-
rest did not happen in all experiment groups (48 h, Ctrl
vs. C225, t = 1.5, P > 0.05; Ctrl vs. 125I-CLDR, t = 0.5,
P > 0.05; Ctrl vs. C225 + 125I-CLDR, t = 1.1, P > 0.05).S
cell cycle decreased in three experiment groups within
48 hours after treatment (48 h, Ctrl vs. C225, t = 5.1,
Figure 2 The antiproliferative effects of C225 and 125-iodine continuous low dose rate radiation. (A) MTS assay for cellular proliferation at
the indicated times after treatment, the exposure dose was 4 Gy (**P < 0.01, compared to C225 + 125I-CLDR group, two-way ANOVA). (B) Cell
cycle distribution at 0 h after treatment, the exposure dose was 4 Gy. (C, D) Cell cycle distribution at the indicated times after treatment. (E)
Morphological analysis after Wright’s-Giemsa staining 48 h after treatment. Arrow indicated a binuclear cell which was a mitotic cell. (F) The
mitotic ratio at 48 h after treatment, the exposure dose was 4 Gy (ns, P > 0.05, unpaired t test was used for data analysis). All data represent three
independent experiments, mean ± SD.
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C225 + 125I-CLDR, t = 11.3, P < 0.001). The cell cycle
distribution between C225 + 125I-CLDR and 125I-CLDR
treated cells shew no significant differences within 48 hours
after treatment (48 h, C225 + 125I-CLDR vs. 125I-CLDR, G1,
t = 0.6, P > 0.05; S, t = 0.1, P > 0.05; G2/M, t = 0.6, P > 0.05)
(Figure 2B, C, D).
We further detected the mitotic ratio at 48 h after treat-
ment in the four groups and found that there were no sig-
nificant differences (48 h, Ctrl vs. C225, t = 1.2, P = 0.4; Ctrl
vs. 125I-CLDR, t = 1.6, P = 0.3; Ctrl vs. C225 + 125I-CLDR,
t = 1.6, P = 0.3; unpaired t test) (Figure 2E, F).
C225 increases radiation-induced cellular apoptosis
We then detected cell death by annexin V-FITC/PI
assay. As shown in Figure 3, both C225 and radiation
induced slight cellular apoptosis when administered
alone (48 h, Ctrl vs. C225, t = 4.9, P = 0.008; Ctrl vs. 125I-
CLDR, t = 4.4, P = 0.012; unpaired t test), and in thecombined treatment, C225 increased radiation-induced
apoptosis (48 h, Ctrl vs. C225 + 125I-CLDR, t = 24.9,
P < 0.001; C225 + 125I-CLDR vs. 125I-CLDR, t = 6.6, P =
0.003; unpaired t test). Furthermore, the Bax/Bcl2 ratio
was increased by C225 and radiation either (24 h, Ctrl
vs. C225, t = 5.9, P = 0.03; Ctrl vs. 125I-CLDR, t = 26.5,
P = 0.0014; unpaired t test) and increased to highest level
by the combined treatment (24 h, Ctrl vs. C225 + 125I-
CLDR, t = 107.4, P < 0.001; unpaired t test). Thus, the
combined treatment produced antiproliferative effects
by inducing cellular apoptosis as a result of imbalance
in the ratio of the pro-apoptotic protein Bax and the
pro-survival protein Bcl2.
C225 reduces the cellular DNA repair capacity
Radiation plays a key role in cancer therapy due to its
ability to directly induce DNA damage. In order to de-
termine the cellular DNA damage and repair, immuno-
fluorescence staining was used to determine the nuclear
Figure 3 C225 increases radiation-induced cellular apoptosis. (A, B) Annexin V-FITC/PI assay was used to detect cellular apoptosis 48 h after
treatment, the exposure dose was 4 Gy. (C, D) The Bax/Bcl2 ratio was determined by Western blot analysis at the indicated times after the
treatment, the exposure dose was 4 Gy. All data represent three independent experiments, mean ± SD. Unpaired t test was used for data analysis.
*P < 0.05, **P < 0.01 as compared to the 125I-CLDR group.
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limited number of cells in the control group exhibiting
γ-H2AX foci (6.5 ± 0.7%). However, cells receiving com-
bined treatment (59.1 ± 2.2%)demonstrated a significant
increase in the γ-H2AX focus-positive cells as compared
to those treated with radiation (48.5 ± 0.1%) or C225
(4.5 ± 3.5%) alone. To determine whether DNA repair
proteins were expressed, western blotting was performed
using lysates from the cells that received the different
treatment protocols. The expression levels of DNA-Pkcs
(48 h, C225 + 125I-CLDR vs. 125I-CLDR, t = 5.7, P = 0.005;
unpaired t test) and Ku70 (48 h, C225 + 125I-CLDR vs. 125I-
CLDR, t = 6.6, P = 0.003; unpaired t test) proteins decreased
with the combined treatment, suggesting that C225 re-
duced the cellular DNA repair capacity by reducing the
DNA-PKcs and Ku70 protein levels.
C225 inhibits Akt activation
When the cancer cells overexpressing EGFR were exposed
to radiation, the survival and proliferation mechanismswere predominantly activated through signaling via PI3K-
Akt and Ras-Erk. Western blot analysis was used to detect
the activation of these two pathways. Our results revealed
that the phosphorylation level of Akt was lower in the cells
receiving the combined treatment (0 h, C225 + 125I-CLDR
vs. C225, t = 9.2, P < 0.001; C225 + 125I-CLDR vs. 125I-
CLDR, t = 7.3, P = 0.0019; unpaired t test) than in those
receiving either treatment alone (0 h, Ctrl vs. C225, t = 2.8,
P = 0.051; Ctrl vs. 125I-CLDR, t = 5.3, P = 0.006; unpaired t
test). However, there were no significant differences in the
activation level of Erk between the different treatment
groups.
Discussion
Preoperative external beam radiotherapy has been shown
to increase pathological complete remission and reduce the
probability of local recurrence; however, this mode of treat-
ment is also associated with increased risk of therapy-
induced side-effects and increased morbidity [3]. High dose
rate brachytherapy has been found to be an alternative to
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ation induces an increase in the EGFR expression in cancer
cells, and blockade of EGFR signaling sensitizes cells to the
effects of radiation [12]. Anti-EGFR monoclonal antibody
C225 has been approved for treating HNSCC in combin-
ation with radiation because of the synergistic effects of
these two treatment approaches [13]. The application of
radiosensitizers to sensitize cancer cells to radiation is a
promising and emerging strategy. Here, we investigated the
capacity of the anti-EGFR mAb C225 to modulate the ra-
diosensitivity and inhibit cellular proliferation in human
colorectal cancer cells.
Our results indicated that C225 enhanced the sensitiv-
ity of LS180 cells to 125I seed radiation (Figure 1). The
relatively lower D0 value suggested that cancer cells
could be killed at reasonably lower doses of radiation
when coupled with C225 (Table 1). Previous studies have
suggested that the capacity of C225 to modulate cancer
cell proliferation and cell cycle distribution might play a
central role in its enhancement of radiosensitivity [14].
Our results demonstrated that continuous exposure
to C225 inhibited LS180 cell proliferation, and this
inhibitory effect was more significant when C225 was
combined with radiation (Figure 2A). The growth inhib-
ition of LS180 cells was mediated by apoptosis induction
(Figure 3) rather than cell cycle arrest (Figure 2B, C,
and D). Moreover, mitotic ratio analysis revealed that
combined treatment did not affect the mitotic index
(Figure 2E and F).
We speculate that the enhancement of radiosensitivity
by C225 is mediated through inhibiting DNA repair.
Among all the radiation-induced damages, DNA double-
strand breaks (DSBs) are the greatest threat to cancer
cells. In eukaryotic cells, DSBs are repaired primarily by
non-homologous end-joining (NHEJ) and homologous
recombination (HR) [15]. NHEJ is a faster and more effi-
cient DSB repair pathway than HR [16], and is the dom-
inant mechanism in mammalian cells. The proteins and
enzymes of NHEJ include Ku70/80, DNA-PKcs, Artemis,
XRCC4, and DNA ligase IV. γ-H2AX foci form at any
nascent DSB, and are first visible approximately 3 min
post-irradiation by immunoflurorescence microscopy,
after which they increase in size until approximately
30 min and then decrease in number with a half-life of
several hours [17]. One γ-H2AX focus correlates to one
DSB, and one DSB remaining unrepaired in a cell can
potentially result in cell death [18]. Recent findings by
Banath et al. [19] suggested that the retained γ-H2AX
foci at 24 hours after treatment were lethal and those γ-
H2AX focus-positive cells would subsequently lose
clonogenicity. Our findings showed that the γ-H2AX
focus-positive cell fraction was higher in the cells that
received the combination therapy than those that re-
ceived C225 or radiation alone (Figure 4A, B, and C).Furthermore, the lowest levels of DNA-PKcs and Ku70
were found in the cells that received the combination
therapy (Figure 4D, E, and F). Therefore, these findings
indicate that C225 impairs DNA repair by reducing the
cellular level of DNA-PKcs and Ku70.
Furthermore, we determined the biochemical processes
responsible for the C225-mediated radiosensitization. An
increasing body of data indicates that the PI3K/AKT- and
Ras/Raf/MEK/ERK-mediated signaling pathways may
govern EGFR-mediated radioresistance [20,21]. In our
study, we found that C225 inhibited Akt activation and
downregulated EGFR expression when combined with
radiation, but did not exert any effects on Erk activa-
tion (Figure 5). The inhibition of PI3K-Akt signaling
was associated with the downregulation of DNA-PKcs
[20]. However, C225-treated cells exhibited EGFR
upregulation, suggesting that the cells developed re-
sistance to C225 [22]. Comfortingly, radiation from
125I downregulated the expression of EGFR protein,
and the cells that received the combination treatment
showed lower EGFR protein levels. Thus, C225 played
opposite roles in the regulation of EGFR protein in
cells treated with or without 125I radiation. However,
the mechanisms underlying these opposing functions
of C225 remain to be elucidated.
Conclusions
Our findings indicate that C225 sensitizes LS180 cells to
125I seed radiation. Growth inhibition was mediated by
inducing apoptosis rather than cell cycle arrest. Add-
itionally, we confirmed that C225 impaired DNA repair
by reducing the cellular level of DNA-PKcs and Ku70
proteins. Furthermore, C225-mediated radiosensitization




The human colon carcinoma cell line LS180 was kindly
provided by the Beijing Institute for Cancer Research.
Cells were grown in RPMI-1640 supplemented with
20 mM HEPES (pH 7.4), 100 IU/mL penicillin, 100 mg/
mL streptomycin, 4 mM glutamine (Gibco, China), and
10% heat-inactivated fetal bovine serum (FBS; Hangzhou
Sijiqing Biological Engineering Materials Company,
China) in a humidified atmosphere of 5% CO2 at 37°C.
Radiation with 125I radioactive seeds and C225 treatment
We used an in vitro 125I seed radiation model that had
been developed in our laboratory [23,24]. In this model,
the exposure times for delivering doses of 1, 2, 4, 6,
8, and 10 Gy were 36, 73.7, 154.6, 245.8, 345.1, and
460.1 hours, respectively. 100 nM C225 was chosen to
treat cells, and the C225 treatment was continuous and
Figure 4 C225 reduces the cellular DNA repair capacity. (A) Formation of γ-H2AX foci (red) in LS180 cells 48 h after the treatment; the nuclei
were stained with Hoechst 33342 (blue); original magnification, ×20. (B) Percentage of γ-H2AX focus-positive cells at 48 h after the treatment. (C)
Mean number of γ-H2AX foci per cell at 48 h. (D) Immunoblotting analysis of DNA-PK(cs), Ku80, Ku70, and actin (loading control) in LS180 cells at the
indicated times after the treatment. Representative analysis of DNA-PKcs (E) and Ku70 (F) protein levels 48 h after the treatment. All data represent
three independent experiments, mean ± SD. Unpaired t test was used for data analysis. ns (not significant) P > 0.05, *P < 0.05, **P < 0.01 as compared
to 125I-CLDR group.
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needs 7 days’ continuous and concurrent C225 treat-
ment when the exposure dose is 4 Gy.
Antibodies
The human-mouse chimeric anti-EGFR monoclonal
antibody (mAb) cetuximab (C225, 5 mg/ml) was pro-
vided by ImClone Systems, Inc. (New York, NY, USA).
The following primary antibodies were purchased
from Cell Signaling Technology (Beverly, MA, USA):
rabbit monoclonal anti-γ-H2AX, anti-EGFR, anti-
Erk1/2, anti-phospho-Erk1/2, anti-Akt, anti-phospho-
Ser473 Akt, anti-Bcl-2, anti-Bax, anti-Ku70, anti-Ku80,
and anti-DNA-PKcs antibodies. The following second-
ary antibodies were obtained for use in this study:
Alexa Fluor 546 goat anti-rabbit IgG (H + L) (Invitrogen,
Carlsbad, CA, USA) and horseradish peroxidase (HRP)-
conjugated anti-rabbit IgG.Colony formation assay
After treatment, the cells were trypsinized to generate a
single cell suspension, and a specific number of trypan
blue-negative cells were seeded into each well of a
six-well tissue culture plate. After the plates were
incubated for 14–21 days, colonies were stained with
Wright’s-Giemsa solution and manually counted.
Colonies containing >50 cells were scored, and three
replicate dishes containing 10–150 colonies per dish
were counted for each treatment.
Cell proliferation assay
After treatment, the cells were trypsinized to generate a sin-
gle cell suspension, plated at 5 × 103 cells/well in 96-well
plates containing 200 μL growth medium, and allowed to
attach for 24 h. At harvest, the medium was removed from
the appropriate wells, replaced with 100 μL MTS solution
(2.5 mg/mL, Beijing PreGene Biotechnology Company, Ltd.
Figure 5 C225 inhibits the activation of Akt and Erk when combined with radiation. (A) Immunoblotting of some proteins involving in
EGFR signaling pathways at the end of treatment (0 h), the exposure dose was 4 Gy. Cells were lysed immediately after treatment. Representative
analysis of the protein levels of EGFR (B), phosphorylated Akt (C), and phosphorylated Erk (D). All data represent three independent experiments,
mean ± SD. Unpaired t test was used for data analysis.
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incubation, the plate was analyzed on a plate reader by
SoftMax program (Molecular Devices Corp., Menlo Park,
CA, USA).Cell cycle analysis
The cells were harvested by trypsinization at the indicated
times after treatment, washed with ice-cold phosphate-
buffered saline (PBS), fixed in 75% ethanol, and stored
at −20°C. Prior to analysis, 1 μg/mL propidium iodide (PI)
and 1 mg/mL RNAse A were used to label the DNA. Flow
cytometry (FACSCalibur, BD Biosciences, San Jose, CA,
USA) was used for cell cycle analysis.Mitotic ratio analysis
Cells were harvested by trypsinization at 48 h after
treatment, treated with ice-cold 0.56% KCl for 3 mi-
nutes, pelleted by centrifugation for 10 min at 400 × g,
resuspended in Carnoy’s fluid (methanol:glacial acetic
acid = 3:1), spread on a slide, air dried, and stained with
Wright’s-Giemsa solution. The binuclear cells were ob-
served under a light microscope.Apoptotic cell death
The Annexin V-FITC/PI assay (Beijing Zoman Biotechnology
Company, Ltd. Beijing, China) was performed according
to the manufacturer’s instructions. Briefly, 5 × 105 cells
were added to 200 μL of staining solution containing
195 μL of apoptosis buffer and 5 μL Annexin V-FITC.
Samples were incubated in the dark at room temperature
or 4°C for 30 minutes, after which 300 μL of apoptosis
buffer was added. Five minutes before analysis, 10 μL PI
was added for chromatin staining. The samples were then
analyzed using a Coulter Epics XL cytometer.
Immunofluorescence staining for γ-H2AX foci
The cells were harvested by trypsinization 48 h after the
treatment, treated with ice-cold 0.56% KCl for 3 minutes,
and pelleted by centrifugation for 10 min at 800 rpm.
The pellets were then resuspended in Carnoy’s fluid
(methanol:glacial acetic acid = 3:1), spread on a slide, air
dried, and rinsed with 95% ethanol and purified water.
Cells were permeabilized in 0.3% Triton X-100 at room
temperature for 15 min, and washed three times for
10 min each in PBS. The cells were then blocked with a
solution of 1% BSA, 0.3% Triton X-100, and PBS (room
temperature) for 2 h, and washed three times for 10 min
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mary monoclonal anti-γ-H2AX antibody (1:400) in 1%
BSA, 0.3% Triton X-100, and PBS overnight at 4°C,
washed in PBS three times for 10 min each, and incu-
bated with Alexa Fluor 546-conjugated secondary anti-
bodies (1:200) for 1 h at room temperature. Thereafter,
the antibodies were washed in PBS four times for
10 min, and counterstained with Hoechst 33342. The cells
were examined on a Zeiss LSM510 confocal scanning
microscope. In a single experiment, cells were counted by
eyes in the stored images (original magnification, ×40) until
at least 100 cells or 100 foci were registered.
Western blot analysis
The treated cells were lysed with Tween-20 lysis buffer
(50 mM HEPES (pH 7.4), 150 mM NaCl, 0.1% Tween-20,
10% glycerol, 2.5 mM EGTA, 1 mM EDTA, 1 mM DTT,
and 1 mM PMSF). Equal amounts of protein were analyzed
by sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE). Thereafter, the proteins were transferred
to nitrocellulose membranes and analyzed by specific
primary antibodies. Proteins were detected with enhanced
chemiluminescence after incubation with horseradish
peroxidase-conjugated secondary antibodies.
Statistical analysis
Data were expressed as mean ± SD. Every experiment was
repeated at least twice. Statistical analysis was performed
using GraphPad Prism software version 5.0 (GraphPad, San
Diego, CA, USA). Student’s t test and ANOVA were used
when appropriate. Differences were considered significant if
P < 0.05.
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